Home Tags Dupixent
Under the new agreement, Paris-based Sanofi would gain sole global rights to Kevzara and sole ex-U.S. rights to Praluent, while Tarrytown’s Regeneron would gain sole U.S. rights to Praluent.
In the U.S., it is indicated for use by prescription to treat moderate-to-severe atopic dermatitis, also known as eczema.
The antibody drug was approved for use in the U,S. last March.
The antibody drug will be marketed as Dupixent and available to adults with moderate to severe atopic dermatitis .
Dupixent will go on the U.S. market this week as the first antibody medicine for uncontrolled itching and rashes in adults with atopic dermatitis.
Total revenues in 2016 for Regeneron, the state’s largest biopharmaceutical employer, rose to $4.86 billion, an 18 percent increase from the previous year.